Median progression-free survival was 6 months.

中位无进展生存期为6个月。

youdao

The median progression-free survival period with the drug combination was 11.8 months, twice as long as the 5.9 months achieved with paclitaxel alone.

药物联用的中值无进展存活期为11.8个月，是用单独紫杉醇获得的5.9个月的两倍。

youdao

Results: of 33 evaluated patients, a 70% overall response rate (complete response plus complete response unconfirmed, 45%) and a median progression-free survival (PFS) of 16.5 months were achieved.

结果：在33个被评估的病人中，总的反应率为70%(完全反应率加未确定的完全反应率，45%)，中位无进展生存期为16.5个月。

youdao

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared to 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant.

WSJ: Roche Breast-Cancer Treatment Advances